You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: ZEBRA BIOLOGICS INC Topic: 300
Project Summary/AbstractRelaxin is a heterodimeric 53 amino acid peptide hormone that induces cardiovascular compliance and reproductive tissue remodeling during pregnancy and parturition. In addition to reproductive organs, the relaxin receptor, RXFP1, is also expressed in the liver, heart, lung, kidney, bone and skin. This broad tissue localization has led to the recognition that relaxin is a pl ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: TENDEL THERAPIES INC Topic: NIAID
This grant will establish immunologic proof-of-concept for a second-generation SARS-CoV-2 vaccine providing extraordinarily durable T-cell and antibody responses, which together protect the respiratory mucosa and minimize the risk of antibody-dependent enhancement (ADE). The vaccine platform combines the immunostimulatory power and proven safety of adenovirus-vectored vaccines with novel in- vecto ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ROCK IMMUNE LLC Topic: 102
Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: K MEDICAL LLC Topic: NINR
Abstract Pressure ulcers or decubitus ulcers, more commonly known as bedsores are a huge problem affecting 2.5 million patients every year in the US and causes 60,000 deaths every year. Pressures exceeding 32 mm of Hg in the bony prominences in the back of the patient body lead to bedsores. Despite the existing low air loss mattresses, alternating pressure mattresses and the state-of-the-art air f ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of mediaSBC: OSSIUM HEALTH INC Topic: 400
ABSTRACT:The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of Goods (COGs). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of co ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: OSSIUM HEALTH INC Topic: NHLBI
PROJECT SUMMARY Mesenchymal stem cells (MSC) are in clinical development for cardiovascular, neurologic, orthopedic, and other indications. Ossium is developing a novel source of MSC from vertebral bodies (vbMSC). Genetic modification of vbMSC using lentiviral vector (LV) has the potential to improve the therapeutic potential. Understanding how genetic modification might alter the vbMSC phenotype ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: SERPLUS TECHNOLOGY LLC Topic: 200
PROJECT SUMMARY The number of people with diabetes worldwide is predicted to increase from 415 million in 2015 to 642 million in 2040. The health care costs of treating diabetes accounts for 12% of the global health expenditure of which Type 1 diabetes mellitus (T1DM) constitutes 10-15% of the disease burden (IDF World Atlas 2015). T1DM is an autoimmune disease triggered by genetic and/or environm ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: NEXILICO, INC. Topic: 100
Project Summary / Abstract Notwithstanding pre-clinical experiments and clinical trials performed to identify efficacy, side effects, and adverse drug reactions (ADRs), only 25-60% of patients respond favorably to prescribed drugs, leading to a cost of $30-$130 billion in the US annually. ADRs are partially attributed to the gut microbiome, i.e. the complex and dynamic community of microorganisms ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: PHOTOPHARMICS, INC. Topic: NIDA
PROJECT SUMMARY Opioid use disorder (OUD) is a rising problem in the United States and around the world, with pain and stress being major factors for initial drug seeking and relapse. The mesolimbic dopamine (DA) system originating in the midbrain ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) in the striatum is an important nexus for the rewarding properties of opioids ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissuesSBC: FORCYTE BIOTECHNOLOGIES, INC. Topic: NIGMS
Project Summary Heart disease remains the leading cause of mortality in the world and, drug-induced cardiotoxicity is a major cause of drug failure and withdrawal from the clinic or the market, contributing to the poor overall success rate of drug development programs. In vitro models of cardiac contractility have the potential to generate predictive data earlier in the pipeline to reduce later-st ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health